{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T20:52:54Z","timestamp":1792356774228,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2005,3,21]],"date-time":"2005-03-21T00:00:00Z","timestamp":1111363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,3,21]],"date-time":"2005-03-21T00:00:00Z","timestamp":1111363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2005,5,1]]},"DOI":"10.1038\/sj.bmt.1704946","type":"journal-article","created":{"date-parts":[[2005,3,21]],"date-time":"2005-03-21T10:03:31Z","timestamp":1111399411000},"page":"971-977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation"],"prefix":"10.1038","volume":"35","author":[{"given":"A","family":"Spencer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H M","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Bashford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Joske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"McKendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Prosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Lowenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Deveridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of The Australasian Leukaemia and Lymphoma Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,3,21]]},"reference":[{"key":"BF1704946_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1600-0609.1999.tb01757.x","volume":"62","author":"M Hjorth","year":"1999","unstructured":"Hjorth M, Holmberg E, Rodjer S et al. Survival in conventionally treated younger (&lt;60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG). Eur J Haematol 1999; 62: 271\u2013277.","journal-title":"Eur J Haematol"},{"key":"BF1704946_CR2","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","volume":"2","author":"TJ McElwain","year":"1983","unstructured":"McElwain TJ, Powles RL . High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822\u2013824.","journal-title":"Lancet"},{"key":"BF1704946_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-2141.1987.tb06890.x","volume":"66","author":"PJ Selby","year":"1987","unstructured":"Selby PJ, McElwain TJ, Nandi AC et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987; 66: 55\u201362.","journal-title":"Br J Haematol"},{"key":"BF1704946_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome (see comments). N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BF1704946_CR5","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.","journal-title":"N Engl J Med"},{"key":"BF1704946_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/stem.5530130722","volume":"13","author":"B Bjorkstrand","year":"1995","unstructured":"Bjorkstrand B, Ljungman P, Bird JM et al. Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. Stem Cells 1995; 13: 140\u2013146.","journal-title":"Stem Cells"},{"key":"BF1704946_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M et al. Comparison of 200\u2009mg\/m(2) melphalan and 8 Gy total body irradiation plus 140\u2009mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial (comment). Blood 2002; 99: 731\u2013735.","journal-title":"Blood"},{"key":"BF1704946_CR8","volume-title":"Clinical Guidelines for the Use of Antineoplastic Agents","author":"FraineAD de","year":"1990","unstructured":"de Fraine AD, Diekman JL, Gaynor GM . In: de Fraine AD, Diekman JL, Gaynor GM (eds). Clinical Guidelines for the Use of Antineoplastic Agents, 3rd edn. PO Box 987, Crows Nest, Sydney NSW 2065, Australia, 1990."},{"key":"BF1704946_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/sj.bmt.1701763","volume":"23","author":"P Moreau","year":"1999","unstructured":"Moreau P, Milpied N, Mahe B et al. Melphalan 220\u2009mg\/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23: 1003\u20131006.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704946_CR10","first-page":"971","volume":"63","author":"JM Yuhas","year":"1979","unstructured":"Yuhas JM . Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep 1979; 63: 971\u2013976.","journal-title":"Cancer Treat Rep"},{"key":"BF1704946_CR11","first-page":"211","volume":"3","author":"JM Yuhas","year":"1980","unstructured":"Yuhas JM, Spellman JM, Culo F . The role of WR-2721 in radiotherapy and\/or chemotherapy. Cancer Clin Trials 1980; 3: 211\u2013216.","journal-title":"Cancer Clin Trials"},{"key":"BF1704946_CR12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/bjc.1980.282","volume":"42","author":"JM Yuhas","year":"1980","unstructured":"Yuhas JM, Spellman JM, Jordan SW et al. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 1980; 42: 574\u2013585.","journal-title":"Br J Cancer"},{"key":"BF1704946_CR13","first-page":"1519","volume":"40","author":"JM Yuhas","year":"1980","unstructured":"Yuhas JM . Active vs passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1980; 40: 1519\u20131524.","journal-title":"Cancer Res"},{"key":"BF1704946_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/00000421-198206000-00015","volume":"5","author":"JL Millar","year":"1982","unstructured":"Millar JL, McElwain TJ, Clutterbuck RD et al. The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR 2721). Am J Clin Oncol 1982; 5: 321\u2013328.","journal-title":"Am J Clin Oncol"},{"key":"BF1704946_CR15","first-page":"1389","volume":"70","author":"AT Turrisi","year":"1986","unstructured":"Turrisi AT, Glover DJ, Hurwitz S et al. Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid]. Cancer Treat Rep 1986; 70: 1389\u20131393.","journal-title":"Cancer Treat Rep"},{"key":"BF1704946_CR16","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.1996.14.7.2101","volume":"14","author":"G Kemp","year":"1996","unstructured":"Kemp G, Rose P, Lurain J et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101\u20132112.","journal-title":"J Clin Oncol"},{"key":"BF1704946_CR17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1590\/S0100-879X2000000700009","volume":"33","author":"CA De Souza","year":"2000","unstructured":"De Souza CA, Santini G, Marino G et al. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study. Brazil J Med Biol Res 2000; 33: 791\u2013798.","journal-title":"Brazil J Med Biol Res"},{"key":"BF1704946_CR18","first-page":"331","volume":"42","author":"JM Yuhas","year":"1969","unstructured":"Yuhas JM, Storer JB . Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 1969; 42: 331\u2013335.","journal-title":"J Natl Cancer Inst"},{"key":"BF1704946_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/03602538908994143","volume":"20","author":"DJ Grdina","year":"1989","unstructured":"Grdina DJ, Sigdestad CP . Radiation protectors: the unexpected benefits. Drug Metab Rev 1989; 20: 13\u201342.","journal-title":"Drug Metab Rev"},{"key":"BF1704946_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1054\/bjoc.2000.1611","volume":"84","author":"JT Hartmann","year":"2001","unstructured":"Hartmann JT, von Vangerow A, Fels LM et al. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer 2001; 84: 313\u2013320.","journal-title":"Br J Cancer"},{"key":"BF1704946_CR21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1046\/j.1365-2141.2000.02149.x","volume":"110","author":"D Capelli","year":"2000","unstructured":"Capelli D, Santini G, De Souza C et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Haematol 2000; 110: 300\u2013307.","journal-title":"Br J Haematol"},{"key":"BF1704946_CR22","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1080\/1042819021000015907","volume":"43","author":"E Jantunen","year":"2002","unstructured":"Jantunen E, Kuittinen T, Nousiainen T . A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients. Leukemia Lymphoma 2002; 43: 1961\u20131965.","journal-title":"Leukemia Lymphoma"},{"key":"BF1704946_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/sj.bmt.1703757","volume":"30","author":"C Thieblemont","year":"2002","unstructured":"Thieblemont C, Dumontet C, Saad H et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 769\u2013775.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704946_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1053\/sonc.2002.37367","volume":"29","author":"GL Phillips Jr","year":"2002","unstructured":"Phillips Jr GL . The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Semin Oncol 2002; 29: 53\u201356.","journal-title":"Semin Oncol"},{"key":"BF1704946_CR25","first-page":"40","volume":"23","author":"LM Schuchter","year":"1996","unstructured":"Schuchter LM . Guidelines for the administration of amifostine. Semin Oncol 1996; 23: 40\u201343.","journal-title":"Semin Oncol"},{"key":"BF1704946_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207\u2013214.","journal-title":"Cancer"},{"key":"BF1704946_CR27","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0140-6736(89)91548-1","volume":"II","author":"ME Gore","year":"1989","unstructured":"Gore ME, Selby PJ, Viner C et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989; II: 879\u2013881.","journal-title":"Lancet"},{"key":"BF1704946_CR28","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115\u20131123.","journal-title":"Br J Haematol"},{"key":"BF1704946_CR29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","volume":"93","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55\u201365.","journal-title":"Blood"},{"key":"BF1704946_CR30","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V95.12.4008","volume":"95","author":"R Desikan","year":"2000","unstructured":"Desikan R, Barlogie B, Sawyer J et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008\u20134010.","journal-title":"Blood"},{"key":"BF1704946_CR31","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/bjc.1995.546","volume":"72","author":"DC Betticher","year":"1995","unstructured":"Betticher DC, Anderson H, Ranson M et al. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small cell lung cancer: a randomised Phase II study. Br J Cancer 1995; 72: 1551\u20131555.","journal-title":"Br J Cancer"},{"key":"BF1704946_CR32","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/(SICI)1097-0142(19970915)80:6<1134::AID-CNCR17>3.0.CO;2-9","volume":"80","author":"GT Budd","year":"1997","unstructured":"Budd GT, Ganapathi R, Adelstein DJ et al. Randomized trial of carboplatin plus amifostine vs carboplatin alone in patients with advanced solid tumors. Cancer 1997; 80: 1134\u20131140.","journal-title":"Cancer"},{"key":"BF1704946_CR33","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/0959-8049(95)00146-A","volume":"31A","author":"L Douay","year":"1995","unstructured":"Douay L, Hu C, Giarratana MC et al. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. Eur J Cancer 1995; 31A: S14\u2013S16.","journal-title":"Eur J Cancer"},{"key":"BF1704946_CR34","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/sj.leu.2401877","volume":"14","author":"A Buschini","year":"2000","unstructured":"Buschini A, Anceschi E, Carlo-Stella C et al. Amifostine (WR-2721) selective protection against melphalan genotoxicity. Leukemia 2000; 14: 1642\u20131651.","journal-title":"Leukemia"},{"key":"BF1704946_CR35","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1182\/blood.V83.11.3132.3132","volume":"83","author":"EJ Shpall","year":"1994","unstructured":"Shpall EJ, Stemmer SM, Hami L et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 1994; 83: 3132\u20133137.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1704946","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704946.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704946.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:25:53Z","timestamp":1648081553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1704946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,21]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,5,1]]}},"alternative-id":["BF1704946"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1704946","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,21]]},"assertion":[{"value":"29 June 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}